2-chloro-n(6)cyclopentyladenosine has been researched along with tacrolimus in 1 studies
| Studies (2-chloro-n(6)cyclopentyladenosine) | Trials (2-chloro-n(6)cyclopentyladenosine) | Recent Studies (post-2010) (2-chloro-n(6)cyclopentyladenosine) | Studies (tacrolimus) | Trials (tacrolimus) | Recent Studies (post-2010) (tacrolimus) |
|---|---|---|---|---|---|
| 252 | 0 | 43 | 17,757 | 2,319 | 6,661 |
| Protein | Taxonomy | 2-chloro-n(6)cyclopentyladenosine (IC50) | tacrolimus (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 7.18 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.58 | |
| Cytochrome P450 3A5 | Homo sapiens (human) | 0.385 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0021 | |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Homo sapiens (human) | 0.2547 | |
| Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform | Homo sapiens (human) | 0.0148 | |
| Splicing factor 3B subunit 3 | Homo sapiens (human) | 0.0123 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 3.3 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 3.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baxter, GF; Hausenloy, DJ; Maddock, HL; Yellon, DM | 1 |
1 other study(ies) available for 2-chloro-n(6)cyclopentyladenosine and tacrolimus
| Article | Year |
|---|---|
Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?
Topics: Adenosine; Analysis of Variance; Animals; Atractyloside; Calcineurin Inhibitors; Cyclosporine; Decanoic Acids; Diazoxide; Enzyme Inhibitors; Hydroxy Acids; Ion Channels; Ischemic Preconditioning, Myocardial; Male; Mitochondria, Heart; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocardial Ischemia; Myocardial Reperfusion Injury; Perfusion; Permeability; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Calcium-Activated; Purinergic P1 Receptor Agonists; Random Allocation; Rats; Rats, Sprague-Dawley; Tacrolimus | 2002 |